Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 221Carcinoma, Non-Small-Cell Lung 218Prostatic Neoplasms 150Multiple Myeloma 140Neoplasms 129Colorectal Neoplasms 117Leukemia, Myeloid, Acute 106Lung Neoplasms 102Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 84Lymphoma 78Melanoma 77Triple Negative Breast Neoplasms 71Pancreatic Neoplasms 71Ovarian Neoplasms 66Sarcoma 64Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Brain Neoplasms 56Lymphoma, Non-Hodgkin 53Hematologic Neoplasms 52Stomach Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 51Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Rectal Neoplasms 46

Interventions

abemaciclib 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinal Cord Neoplasms × 90 days × Clear all
NCT06413706 2026-05-22

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Eli Lilly and Company

Phase 2 Active not recruiting
45 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡